Cohero Health said today that it oversubscribed its $9 million Series A round with investments from Samsung Next and Omron Healthcare
The latest contributions will be used to support commercialization of hardware and software for its BreatheSmart connected respiratory disease management platform, the N.Y.-based company said.
“BreatheSmart from Cohero Health provides both connected hardware and software as an integrated platform, with a high attention to usability – this is no easy feat. We are especially impressed with how the team developed their range of mobile spirometers, which required significant work around manufacturing, clinical efficacy and regulatory approval,” Amit Garg, principal at Samsung Next, said in prepared remarks. “We are looking into how healthtech startups can use software and services to make a disruptive impact into chronic disease management. Cohero Health has created a great solution for respiratory care, tackling the opportunity to help 50 million Americans and 300 million worldwide who suffer from asthma and COPD.”
“Our goal is to ensure that every respiratory patient is empowered to take control of their health, and to prevent avoidable hospital and emergency room visits as a result of uncontrolled respiratory issues,” Omron Healthcare exec Kenji Eda added. “We believe that there is a huge opportunity for Cohero Health and Omron Healthcare to collaborate on the introduction of new products and services linked to BreatheSmart, giving patients and healthcare providers deeper insight into patient health, and reducing the risk of future negative events.”
“Samsung Next and Omron Healthcare support our mission to improve respiratory care through smart mobile devices. These leading technology companies have the scale and expertise that are invaluable to early stage companies like ours,” Cohero co-founder & CEO Melissa Manice said. “We see significant benefit in partnering with well established organizations such as Samsung and Omron Healthcare, while we remain focused on achieving platform scalability through interoperability and effective respiratory stakeholder collaboration.”
In February, the company raised more than $13.3 million, according to regulatory filings, in equity and Series A preferred stock. Cohero sold nearly all of its total offering amount of $13.6 million before closing the round. Over 50 investors have contributed to the offering, which had its 1st sale in October last year.